Profile data is unavailable for this security.
About the company
Shanghai Shen Lian Biomedical Corp is a China-based company mainly engaged in the research, development, production and sales of veterinary biological products. The Company is committed to the research & development of foot and mouth disease vaccines, which are used to protect animals from foot and mouth diseases. The Company's main product are swine foot and mouth disease vaccines, and it also provides cattle foot and mouth disease vaccines, other swine vaccines, and other veterinary diagnostic reagents. The Company mainly sells its products within domestic market.
- Revenue in CNY (TTM)304.79m
- Net income in CNY-12.92m
- Incorporated2001
- Employees380.00
- LocationShanghai Shen Lian Biomedical CorpNo. 48Jiangchuan East Road, Minhang DistrictSHANGHAI 200241ChinaCHN
- Phone+86 2 161257979
- Fax+86 2 161267296
- Websitehttp://www.slbio.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Shen Lian Biomedical Corp | 304.79m | -12.92m | 2.05bn | 380.00 | -- | 1.42 | -- | 6.72 | -0.0315 | -0.0315 | 0.7422 | 3.51 | 0.196 | 0.9229 | 1.15 | 802,082.80 | -1.06 | 5.39 | -1.12 | 5.84 | 64.36 | 77.45 | -5.42 | 25.48 | 5.16 | -- | 0.0015 | 38.49 | -8.25 | 1.85 | -48.41 | -18.49 | 10.47 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 197.30m | 50.92m | 2.06bn | 321.00 | 40.44 | 1.85 | -- | 10.44 | 0.4706 | 0.4706 | 1.82 | 10.30 | 0.1735 | 1.14 | 3.91 | 614,647.90 | 4.48 | 10.43 | 4.56 | 10.84 | 76.60 | 80.54 | 25.81 | 32.57 | 42.72 | -- | 0.004 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Hanshang Group Co Ltd | 1.28bn | -5.18m | 2.22bn | 2.38k | -- | 1.29 | -- | 1.73 | -0.016 | -0.016 | 4.31 | 5.80 | 0.362 | 2.52 | 8.04 | 536,620.30 | -0.4451 | 2.00 | -0.7501 | 3.89 | 53.60 | 57.24 | -1.23 | 4.89 | 0.2688 | 1.18 | 0.3163 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
Data as of Nov 01 2024. Currency figures normalised to Shanghai Shen Lian Biomedical Corp's reporting currency: Chinese Yuan Renminbi CNY
2.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gfund Management Co., Ltd.as of 30 Jun 2024 | 1.99m | 0.79% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 1.39m | 0.55% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 1.37m | 0.54% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024 | 149.80k | 0.06% |
| JX Asset Management Co.,Ltdas of 30 Jun 2024 | 90.00k | 0.04% |
| Truvalue Asset Management Co. Ltd.as of 30 Jun 2024 | 67.20k | 0.03% |
| Springs Fund Management Co. Ltd.as of 30 Jun 2024 | 18.40k | 0.01% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 9.70k | 0.00% |
| Minsheng Royal Fund Management Co., Ltd.as of 30 Jun 2024 | 1.60k | 0.00% |
| Great Wall Fund Management Co., Ltd.as of 30 Jun 2024 | 73.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
